

Neuroferritinopathy

Description

Neuroferritinopathy is a disorder in which iron gradually accumulates in the brain. Certain brain regions that help control movement (basal ganglia) are particularly affected. People with neuroferritinopathy have progressive problems with movement that begin at about age 40. These movement problems can include involuntary jerking motions (chorea), rhythmic shaking (tremor), difficulty coordinating movements (ataxia), or uncontrolled tensing of muscles (dystonia). Symptoms of the disorder may be more apparent on one side of the body than on the other. Affected individuals may also have difficulty swallowing (dysphagia) and speaking (dysarthria).

Intelligence is unaffected in most people with neuroferritinopathy, but some individuals develop a gradual decline in thinking and reasoning abilities (dementia). Personality changes such as reduced inhibitions and difficulty controlling emotions may also occur as the disorder progresses.

Frequency

The prevalence of neuroferritinopathy is unknown. Fewer than 100 individuals with this disorder have been reported.

Causes

Mutations in the *FTL* gene cause neuroferritinopathy. The *FTL* gene provides instructions for making the ferritin light chain, which is one part (subunit) of a protein called ferritin. Ferritin stores and releases iron in cells. Each ferritin molecule can hold as many as 4,500 iron atoms. This storage capacity allows ferritin to regulate the amount of iron in the cells and tissues.

Mutations in the *FTL* gene that cause neuroferritinopathy are believed to reduce ferritin's ability to store iron, resulting in the release of excess iron in nerve cells (neurons) of the brain. The cells may respond by producing more ferritin in an attempt to handle the free iron. Excess iron and ferritin accumulate in the brain, particularly in the basal ganglia, resulting in the movement problems and other neurological changes seen in neuroferritinopathy.

Learn more about the gene associated with Neuroferritinopathy

FTL

Inheritance

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

In most cases, an affected person inherits the mutation from one affected parent. Other cases may result from new mutations in the gene. These cases occur in people with no history of the disorder in their family.

Other Names for This Condition

- Basal ganglia disease, adult-onset
- Ferritin-related neurodegeneration
- Hereditary ferritinopathy
- NBIA3
- Neurodegeneration with brain iron accumulation 3

Additional Information & Resources

Genetic Testing Information

Genetic Testing Registry: Neuroferritinopathy (https://www.ncbi.nlm.nih.gov/gtr/conditions/C1853578/)

Genetic and Rare Diseases Information Center

Neuroferritinopathy (https://rarediseases.info.nih.gov/diseases/10686/index)

Patient Support and Advocacy Resources

National Organization for Rare Disorders (NORD) (https://rarediseases.org/)

Clinical Trials

ClinicalTrials.gov (https://clinicaltrials.gov/search?cond=%22Neuroferritinopathy%2
 2)

Catalog of Genes and Diseases from OMIM

NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 3; NBIA3 (https://omim.org/entry/606159)

Scientific Articles on PubMed

PubMed (https://pubmed.ncbi.nlm.nih.gov/?term=%28%28neuroferritinopathy%5BT IAB%5D%29+OR+%28hereditary+ferritinopathy%5BTIAB%5D%29%29+AND+engli sh%5BIa%5D+AND+human%5Bmh%5D+AND+%22last+2160+days%22%5Bdp%5D)

References

- Burn J, Chinnery PF. Neuroferritinopathy. Semin Pediatr Neurol. 2006Sep;13(3): 176-81. doi: 10.1016/j.spen.2006.08.006. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/17101456)
- Burn J. Neuroferritinopathy: iron in the brain. Mol Cytogenet. 2014 Jan21;7(Suppl 1 Proceedings of the International Conference on Human):I36. doi:10.1186/1755-8166-7-S1-I36. eCollection 2014. No abstract available. Citation on PubMed (https://pubm ed.ncbi.nlm.nih.gov/24949097) or Free article on PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044225/)
- Crompton DE, Chinnery PF, Bates D, Walls TJ, Jackson MJ, Curtis AJ, Burn J.
 Spectrum of movement disorders in neuroferritinopathy. Mov Disord. 2005Jan;20(1): 95-9. doi: 10.1002/mds.20284. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/15390132)
- Keogh MJ, Jonas P, Coulthard A, Chinnery PF, Burn J. Neuroferritinopathy: anew inborn error of iron metabolism. Neurogenetics. 2012 Feb;13(1):93-6. doi:10.1007/s10048-011-0310-9. Epub 2012 Jan 26. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/22278127) or Free article on PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038507/)
- Keogh MJ, Morris CM, Chinnery PF. Neuroferritinopathy. Int Rev Neurobiol.2013; 110:91-123. doi: 10.1016/B978-0-12-410502-7.00006-5. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/24209436)
- Lehn A, Boyle R, Brown H, Airey C, Mellick G. Neuroferritinopathy.Parkinsonism Relat Disord. 2012 Sep;18(8):909-15. doi:10.1016/j.parkreldis.2012.06.021. Epub 2012 Jul 17. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/22818529)
- Levi S, Cozzi A, Arosio P. Neuroferritinopathy: a neurodegenerative disorderassociated with L-ferritin mutation. Best Pract Res Clin Haematol. 2005Jun; 18(2):265-76. doi: 10.1016/j.beha.2004.08.021. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/15737889)
- McNeill A, Chinnery PF. Neuroferritinopathy: update on clinical features andpathogenesis. Curr Drug Targets. 2012 Aug;13(9):1200-3. doi:10.2174/ 138945012802002375. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/22515 742)

 Vidal R, Ghetti B, Takao M, Brefel-Courbon C, Uro-Coste E, Glazier BS, SianiV, Benson MD, Calvas P, Miravalle L, Rascol O, Delisle MB. Intracellular ferritinaccumulation in neural and extraneural tissue characterizes a neurodegenerativedisease associated with a mutation in the ferritin light polypeptide gene. JNeuropathol Exp Neurol. 2004 Apr;63(4):363-80. doi: 10.1093/jnen/63.4.363. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/15099026)

Last updated August 1, 2014